Latest Competition News

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Cavalier Resources’ 2026 Pre-Feasibility Study update boosts the Stage 1 NPV of its Crawford Gold Project to A$77.2 million at A$6,500/oz gold, reflecting resilience amid supply chain pressures. The project maintains its ore reserve and pit design, with financing negotiations advancing.

Hiremii Limited has landed its initial paying customers for its AI-powered workforce intelligence platform, marking a pivotal step in its shift from recruitment services to a SaaS technology provider in energy and infrastructure sectors.

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Vysarn Limited's joint venture with Kariyarra Aboriginal Corporation has been shortlisted by Water Corporation to submit a formal proposal for supplying bulk water to Port Hedland, progressing key regulatory approvals for the Kariyarra Water Scheme.

Elevate Uranium announces a maiden Inferred Mineral Resource of 10.1 million pounds U3O8 at Namib IV, boosting the Koppies Project resource to 76.2 Mlb and Namibia’s total uranium inventory to 106.4 Mlb. The deposit remains open for expansion amid ongoing drilling and proprietary processing developments.

Yancoal Australia is set to acquire an 80% stake in the Kestrel Coal Mine for US$1.85 billion upfront plus up to US$550 million in contingent payments, significantly boosting its metallurgical coal portfolio and production scale in Queensland.

Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.

Michael Hill International’s 2026 Investor Day highlights sustained sales growth, a streamlined brand portfolio, and a disciplined return to dividends, underpinned by AI-driven retailing and a reset of the Bevilles brand.

Pointerra has landed a three-year, A$0.4 million deal with Western Power to roll out its Pointerra3D digital twin platform across transmission substations in Western Australia, marking a significant foothold in the domestic energy utility sector.